Concentra Group Holdings Parent (CON) Q1 2025 earnings summary

Executive summary

• Q1 2025 delivered strong year-over-year growth: revenue up 7.1% to $500.8 million and adjusted EBITDA up 6.8% to $102.7 million, driven by visit growth, rate increases, and major acquisitions including Nova Medical Centers and the signing of the Pivot OnSite Innovations deal.

• Net income declined to $38.9–$40.6 million, primarily due to higher interest and administrative expenses following recapitalization and acquisitions.

• Facility count increased to 627 occupational health centers and 160 onsite clinics, with Nova and PHC acquisitions adding 72 centers and Pivot OnSite expected to double onsite clinic footprint.

• Maintained quarterly dividend of $0.0625 per share and successfully refinanced senior debt.

• Patient visits rose 1.5% to 3.2 million, with visits per day up 3.2% year-over-year.

Financial highlights

• Revenue for Q1 2025 was $500.8 million, up from $467.6 million in Q1 2024 (7.1% growth); adjusted EBITDA reached $102.7 million (20.5% margin), up from $96.1 million (20.6% margin) in Q1 2024.

• Net income was $38.9–$40.6 million (7.8–8.1% margin), down from $49.0–$50.3 million (10.5–10.8% margin) in Q1 2024, with adjusted EPS at $0.32 (vs. $0.49 prior year).

• Cost of services was $357.1 million (71.3% of revenue), down from 72.1% prior year, reflecting operational efficiencies.

• Operating cash flow was $11.7 million, impacted by seasonality and higher interest payments.

• Capital expenditures for Q1: $15.7 million.

Outlook and guidance

• 2025 revenue guidance raised to $2.1–$2.15 billion; adjusted EBITDA guidance raised to $415–$430 million.

• Capital expenditures expected at $80–$90 million; net leverage target remains ~3.5x for year-end 2025, with a goal of ~3.0x in 18–24 months.

• Anticipate limited M&A for the rest of 2025, with free cash flow targeted for debt repayment.

• Management expects continued growth through strategic acquisitions and de novo center openings.